Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$257 Mln
P/E Ratio
--
P/B Ratio
0.58
Industry P/E
--
Debt to Equity
0
ROE
-0.34 %
ROCE
-33.74 %
Div. Yield
0 %
Book Value
5.22
EPS
-2
CFO
$-17.37 Mln
EBITDA
$-190.79 Mln
Net Profit
$-164.06 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
| -11.34 | -3.57 | -10.81 | -20.59 | -23.33 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
| 9.75 | -36.59 | -46.20 | -78.60 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a... nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Address: 225 Franklin Street, Boston, MA, United States, 02110 Read more
Founder, Chairman, CEO & President
Dr. Jean-Pierre Sommadossi Ph.D.
Founder, Chairman, CEO & President
Dr. Jean-Pierre Sommadossi Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Atea Pharmaceuticals Inc (AVIR) stood at $ 465 Mln as on 31-Dec-24
The share price of Atea Pharmaceuticals Inc (AVIR) is $2.97 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Atea Pharmaceuticals Inc (AVIR) has given a return of -23.33% in the last 3 years.
Atea Pharmaceuticals Inc (AVIR) has a market capitalisation of $ 257 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Atea Pharmaceuticals Inc (AVIR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Atea Pharmaceuticals Inc (AVIR) and enter the required number of quantities and click on buy to purchase the shares of Atea Pharmaceuticals Inc (AVIR).
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Address: 225 Franklin Street, Boston, MA, United States, 02110
The CEO & director of Dr. Jean-Pierre Sommadossi Ph.D.. is Atea Pharmaceuticals Inc (AVIR), and CFO & Sr. VP is Dr. Jean-Pierre Sommadossi Ph.D..
There is no promoter pledging in Atea Pharmaceuticals Inc (AVIR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Atea Pharmaceuticals Inc. (AVIR) | Ratios |
|---|---|
|
Return on equity(%)
|
-33.88
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Atea Pharmaceuticals Inc (AVIR) was $0 Mln.
$-0.03
(
